Literature DB >> 28238033

Clinical and multiparametric MRI signatures of granulomatous prostatitis.

Soroush Rais-Bahrami1,2, Jeffrey W Nix3, Baris Turkbey4, Jason A Pietryga5, Rupan Sanyal5, John V Thomas5, Jennifer B Gordetsky3,6.   

Abstract

PURPOSE: The purpose of the study is to differentiate granulomatous prostatitis (GP) from high-grade prostate cancer (PCa) based on clinical findings and imaging characteristics on multiparametric MRI (MP-MRI).
METHODS: Pathology from patients undergoing MRI/US fusion-guided prostate biopsies between 2014 and 2015 was reviewed. Five patients with biopsy proven GP were identified as well as 15 patients with biopsy-proven Gleason score ≥4 + 3 = 7 PCa. Patients were matched for age, serum PSA level, and prebiopsy-assigned MP-MRI cancer suspicion scores. MP-MRI studies were reviewed to identify findings that would differentiate GP from PCa in patients who had equally high suspicion scores based upon imaging characteristics.
RESULTS: All five patients with GP on MR/US fusion-targeted biopsies were assigned a PIRADS 4 or 5 suspicion score. There were equally high suspicion scores on MP-MRI for both groups (p = 0.57). Re-evaluation of the MRI characteristics of the 5 GP patients and 15 matched controls who had pathologically proven Gleason score ≥4 + 3 = 7 PCa on targeted biopsy demonstrated statistically lower mean ADC values within the index targeted lesion for PCa vs. GP (p = 0.002) Qualitatively, no patients with GP on biopsy had imaging evidence of higher-staged disease, while 33% of patients in the high-risk PCa cohort demonstrated at least one high-stage feature (p = 0.003).
CONCLUSION: Patients with GP routinely have MRIs with moderate to high levels of suspicion for harboring PCa. Re-evaluation of these patients' imaging demonstrated characteristics including significantly higher ADC values and absence of high-stage features, which may help differentiate areas of GP from PCa in the future.

Entities:  

Keywords:  Apparent diffusion coefficient; Granuloma; Magnetic resonance imaging; Prostate adenocarcinoma; Tuberculosis

Mesh:

Substances:

Year:  2017        PMID: 28238033     DOI: 10.1007/s00261-017-1080-0

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  6 in total

1.  BCG instillations can mimic prostate cancer on multiparametric MRI.

Authors:  Pablo Garrido-Abad; Miguel Ángel Rodríguez-Cabello; Cristina González-Gordaliza; Roberto Vera-Berón; Arturo Platas-Sancho
Journal:  Int Braz J Urol       Date:  2018 Jul-Aug       Impact factor: 1.541

2.  Multiparametric MRI appearances of primary granulomatous prostatitis.

Authors:  Su-Min Lee; Konrad Wolfe; Peter Acher; Sidath H Liyanage
Journal:  Br J Radiol       Date:  2019-04-09       Impact factor: 3.039

3.  Histologic findings associated with false-positive multiparametric magnetic resonance imaging performed for prostate cancer detection.

Authors:  Jennifer B Gordetsky; David Ullman; Luciana Schultz; Kristin K Porter; Maria Del Carmen Rodriguez Pena; Carli E Calderone; Jeffrey W Nix; Michael Ullman; Sejong Bae; Soroush Rais-Bahrami
Journal:  Hum Pathol       Date:  2018-09-01       Impact factor: 3.466

4.  Granulomatous prostatitis with high suspicion of prostatic adenocarcinoma on radiological imaging.

Authors:  Yoshiki Ambe; Masaki Nakamura; Norihide Shirakawa; Hiroki Inatsu; Ryo Amakawa; Yasushi Inoue; Tadashi Yoshimatsu; Sakiko Miura; Teppei Morikawa; Masashi Kusakabe; Yoshiyuki Shiga
Journal:  IJU Case Rep       Date:  2021-05-06

Review 5.  Prostate imaging features that indicate benign or malignant pathology on biopsy.

Authors:  Catherine Elizabeth Lovegrove; Mudit Matanhelia; Jagpal Randeva; David Eldred-Evans; Henry Tam; Saiful Miah; Mathias Winkler; Hashim U Ahmed; Taimur T Shah
Journal:  Transl Androl Urol       Date:  2018-09

6.  Granulomatous prostatitis mimicking prostate cancer in a patient with psoriatic arthritis: a case report.

Authors:  Luigi De Luca; Felice Crocetto; Biagio Barone; Massimiliano Creta; Salvatore Pesce; Achille Aveta; Maria Raffaela Campanino; Ciro Imbimbo; Nicola Longo
Journal:  Future Sci OA       Date:  2020-06-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.